Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(DGI, CLF, PWRM, CLC, ICLR) Noticeable Stock by

Stock-PR Reporting



FREE Daily Stock Alerts From


DigitalGlobe, Inc. (NYSE:DGI) a leading global provider of high-resolution earth imagery solutions, said that California's Stanislaus County has contracted to use its Precision Aerial Imagery to monitor changes and manage government projects across the Central Valley county's 1,500 square mile (3,900 square kilometer) area. DigitalGlobe's Precision Aerial product delivers the industry's first high-quality, wall-to-wall collection of 30 cm natural color (RGB) and 60 cm color infrared (NYSE:CIR) aerial orthomosaics covering 10 million square kilometers (four million square miles) across the contiguous United States and Western Europe. Through an agreement with Microsoft, premium quality imagery is acquired exclusively using Microsoft's UltraCamG digital imaging technology to provide comprehensive coverage with industry leading accuracy, quality and aesthetics.

DigitalGlobe, Inc. provides commercial earth imagery products and solutions. The company collects its imagery products and services via its three high-resolution imagery satellites. DigitalGlobe was incorporated in 1994 and is headquartered in Longmont, Colorado. DigitalGlobe, Inc. is a subsidiary of Morgan Stanley & Co. Incorporated.


Cliffs Natural Resources Inc. (NYSE:CLF) announced David Webb will join the organization as senior vice president, global coal effective July 18, 2011. In this position, Mr. Webb will provide strategic leadership and drive operational performance at the Company's coal operations in North America, including two underground longwall operations and three continuous mining operations. He reports to Duncan Price, executive vice president, president - global operations.

Cliffs Natural Resources Inc. is an international mining and natural resources company. A member of the S&P 500 Index, the Company is a major global iron ore producer and a significant producer of high- and low-volatile metallurgical coal. News releases and other information on the Company are available on the Internet at:


power3 Power3 Medical Products, Inc. (OTC:PWRM)

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).

Many women who develop breast cancer have no risk factors other than age and sex.

Gender is the biggest risk because breast cancer occurs mostly in women.

Age is another critical factor. Breast cancer may occur at any age, though the risk of breast cancer increases with age. The average woman at age 30 years has one chance in 280 of developing breast cancer in the next 10 years. This chance increases to one in 70 for a woman aged 40 years, and to one in 40 at age 50 years. A 60-year-old woman has a one in 30 chance of developing breast cancer in the next 10 years.

Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminate function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

Please visit Power3 Medical Products, Inc website


CLARCOR Inc. (NYSE:CLC) Board of Directors at its June board meeting declared a regular quarterly dividend of $0.105 per share of common stock. The dividend will be paid on Friday, July 22, 2011 to shareholders of record July 8, 2011.

CLARCOR is based in Franklin, Tennessee and is a diversified marketer and manufacturer of mobile, industrial and environmental filtration products and consumer and industrial packaging products sold in domestic and international markets.


ICON plc (Nasdaq:ICLR) announced ICONIK, an integrated technology solution that provides a single view of study information to both sponsor and CRO teams anytime, anywhere. ICONIK provides immediate knowledge to study teams by allowing near real-time access to study performance metrics, critical safety and efficacy data, and analysis of this data in new and unique ways. ICONIK consolidates and standardises data from multiple sources, including CTMS, EDC, IVR and ePRO, and combines the data with analytical, reporting and visualisation tools to provide a single view of study information. Both CRO and sponsor teams can easily access study information and trends anytime, anywhere from a secure, web-based interface. A 21CFR compliant solution, ICONIK enables sponsors to more easily meet regulatory requirements by providing an online, end-to-end audit trail of study data for FDA submissions and post-submission queries.

CON plc, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries primarily in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support clinical development from compound selection to Phase I to IV clinical studies.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Sign Up For Free Stock Alerts At